|
Getting your Trinity Audio player ready...
|
Active Stocks Releasing News Recently to Watch Now: Myseum, Inc. (NASDAQ: MYSE), SurgePays, Inc. (NASDAQ: SURG), ENDRA Life Sciences (NASDAQ: NDRA), Scienjoy Corp (NASDAQ: SJ), Roadzen Inc (NASDAQ: RZDN), Kartoon Studios, Inc (NYSE: TOON), Power Metallic Mines (TSX-V: PNPN | OTCQB: PNPNF), Synergy CHC Corp. (NASDAQ: SNYR), Peraso Inc (NASDAQ: PRSO) and Datavault AI (NASDAQ: DVLT) — all active in trading sessions and should be added to your radar now as momentum accelerates across the small-cap biotech, tech, media and AI sectors.
now as momentum accelerates across the small-cap biotech, tech, media and AI sectors.
Polyrizon Ltd. (Nasdaq: PLRZ) soared more than 100% in after-hours trading after announcing powerful new preclinical data demonstrating that its proprietary intranasal naloxone hydrogel exhibits significantly superior mucoadhesion compared to a marketed intranasal naloxone spray — a critical performance advantage for real-world opioid overdose emergencies.
Using an established ex-vivo rabbit nasal mucosa model, researchers compared the persistence of Polyrizon’s hydrogel to a commercial naloxone product under repeated washing with Simulated Nasal Electrolyte Solution (SNES). Polyrizon’s Trap & Target™ (T&T) hydrogel retained dramatically higher fluorescence levels, with results reaching p < 0.0001, demonstrating far stronger and more durable mucosal adhesion.
Enhanced mucoadhesion is a key driver of intranasal drug delivery performance — particularly for emergency opioid overdose reversal — because increased nasal residence time supports more reliable absorption and potentially faster onset of action.
“These results further validate the potential of our T&T hydrogel platform,” said Tomer Izraeli, CEO of Polyrizon. “Outperforming a marketed product in mucoadhesion is a significant milestone for our Naloxone program.”
The new findings build on Polyrizon’s previously reported stability data, reinforcing the Company’s positioning in intranasal drug delivery, biodefense, and next-generation hydrogel-based therapeutics. With global opioid overdose deaths continuing to rise, Polyrizon’s innovation may represent a meaningful improvement in emergency response tools.
Investors now anticipate next steps including preclinical advancement, regulatory pathway updates, and future clinical development as Polyrizon moves toward what could become a best-in-class intranasal naloxone product. For more information, visit www.polyrizon-biotech.com.